TrialEuropean journal of clinical pharmacology2018

Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.

Fredrik N Albach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.